- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Ocugen, Inc (OCGN)
Ocugen, Inc stock price live, this page displays NASDAQ OCGN stock exchange data. View the OCGN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Ocugen, Inc real time stock price chart below.
What Is the Ocugen, Inc Stock Price Today?
The Ocugen, Inc stock price today is 2.040.
What Is the Stock Symbol for Ocugen, Inc?
The stock symbol for Ocugen, Inc is "OCGN."
What Stock Exchange Does Ocugen, Inc Trade On?
Ocugen, Inc is listed and trades on the NASDAQ stock exchange.
Is Ocugen, Inc a Good Stock to Buy?
Determining whether Ocugen, Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OCGN quote. (ISIN: US67577C1053)
What Is the Ocugen, Inc Stock Price Today?
The Ocugen, Inc stock price today is 2.040.
What Is the Stock Symbol for Ocugen, Inc?
The stock symbol for Ocugen, Inc is "OCGN."
What Stock Exchange Does Ocugen, Inc Trade On?
Ocugen, Inc is listed and trades on the NASDAQ stock exchange.
Is Ocugen, Inc a Good Stock to Buy?
Determining whether Ocugen, Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the OCGN quote. (ISIN: US67577C1053)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.010
2.280
52 wk Range
0.570
2.725
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.0102.280
52 wk Range
0.5702.725
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
OCGN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
10.597
Upside
+419.47%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 8K Ocugen, Inc For: 20 March
- Investing.com
- Histogenics Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 8K Ocugen, Inc For: 20 March
- Investing.com
- Histogenics Corp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Ocugen, Inc Earnings Call Summary for Q4/2025
- Ocugen reported Q4 2025 net loss of $0.06/share, meeting forecasts; stock fell 5.38% pre-market to $1.93 with $641M market cap.
- R&D expenses surged 28.9% YoY to $10.7M as company advances retinitis pigmentosa and Stargardt disease clinical programs.
- Company projects -$0.05 EPS quarterly for FY2026; cash runway extends into late 2026, potentially Q2 2027 with warrant exercises.
- Analyst price targets range $7-$15 despite no anticipated profitability this year; key clinical trial completions expected ahead.
- G&A expenses decreased 3.2% to $6.1M; management emphasizes long-term commercialization strategy amid ongoing losses and no revenue.
Last Updated: 2026-03-04, 10:14 a/m
Read Full TranscriptCompare OCGN to Peers and Sector
Metrics to compare | OCGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOCGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.9x | −2.7x | −0.5x | |
PEG Ratio | 0.74 | −0.08 | 0.00 | |
Price/Book | −55.0x | 2.7x | 2.6x | |
Price / LTM Sales | 151.6x | 15.7x | 3.1x | |
Upside (Analyst Target) | 292.2% | 184.9% | 57.5% | |
Fair Value Upside | Unlock | 19.5% | 8.6% | Unlock |
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.597
(+419.47% Upside)
Earnings
Latest Release
Mar 04, 2026
EPS / Forecast
-0.06 / -0.06
Revenue / Forecast
-193K / 1.03M
People Also Watch
FAQ
What Is the Ocugen (OCGN) Stock Price Today?
The Ocugen stock price today is 2.040 USD.
What Stock Exchange Does Ocugen Trade On?
Ocugen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Ocugen?
The stock symbol for Ocugen is "OCGN."
What Is the Ocugen Market Cap?
As of today, Ocugen market cap is 668.910M USD.
What Is Ocugen's Earnings Per Share (TTM)?
The Ocugen EPS (TTM) is -0.226.
When Is the Next Ocugen Earnings Date?
Ocugen will release its next earnings report on May 01, 2026.
From a Technical Analysis Perspective, Is OCGN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Ocugen Stock Split?
Ocugen has split 1 times.
How Many Employees Does Ocugen Have?
Ocugen has 116 employees.
What is the current trading status of Ocugen (OCGN)?
As of Mar 22, 2026, Ocugen (OCGN) is trading at a price of 2.040 USD, with a previous close of 2.240 USD. The stock has fluctuated within a day range of 2.010 USD to 2.280 USD, while its 52-week range spans from 0.570 USD to 2.725 USD.
What Is Ocugen (OCGN) Price Target According to Analysts?
The average 12-month price target for Ocugen is 10.597 USD, with a high estimate of 22 USD and a low estimate of 7 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +419.47% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.